Brenus Pharma is a French clinical-stage biotechnology company developing a new class of in vivo immunotherapies for solid tumors.

The company has built a proprietary, data-driven platform based on its Stimulated-Ghost-Cell (SGC) technology. It transforms tumor complexity into scalable, off-the-shelf therapeutic candidates by integrating multi-omics data, predictive validation models, and GMP-ready manufacturing. This approach enables cost control and broad patient access, overcoming key limitations of personalized therapies such as mRNA and CAR-T.

SGC technology reproduces tumor protein expression and makes these targets visible to the immune system. It captures tumor heterogeneity, including resistance and plasticity, and enables broad, multi-specific immune responses against evolving tumors.

The lead candidate, STC-1010, targets metastatic colorectal cancer, the second leading cause of cancer-related death worldwide. It is currently evaluated in a Phase I/II trial (NCT06934538) in advanced MSS CRC. Early data show a favorable safety profile and initial signs of immune engagement.

Upcoming milestones include U.S. IND submission, clinical data readouts, and a Series B financing.